Tryptase, Serum (Total)
The Serum Tryptase test quantifies total tryptase — the combined alpha and beta mast-cell-specific protease fractions — serving two temporally distinct clinical roles: acute tryptase collected 30–120 minutes post-reaction confirms mast cell degranulation in anaphylaxis when peak levels meet the formula threshold (≥ 1.2 × individual baseline + 2 ng/mL);
1
Biomarkers
Blood (serum)
Sample
1–3 business days
Turnaround
No — however, specimen collection timing relative to any acute allergic or anaphylactic event is the critical pre-analytical variable superseding all other preparation requirements. For acute post-reaction specimens: collect between 30 and 120 minutes after event onset for peak tryptase assessment. For baseline specimens: collect at least 24 hours after any acute mast cell activation event and in the absence of current acute symptoms.
Fasting
What is the Serum Tryptase test?
The Serum Tryptase test quantifies total tryptase — the combined alpha and beta fractions — providing the most clinically specific serum marker of mast cell mass and acute mast cell degranulation activity available through routine clinical laboratory networks. It is ordered in two fundamentally different clinical contexts that require different specimen timing, result interpretation frameworks, and clinical action pathways, and practitioners must specify which context applies at the time of ordering. In the acute context — collected 30–120 minutes following a suspected anaphylactic or severe allergic reaction, venom sting, drug reaction, or unexplained cardiovascular or respiratory collapse — an elevated tryptase above the diagnostic threshold (peak ≥ 1.2 × individual baseline + 2 ng/mL, or peak >11.4 ng/mL in the absence of a known personal baseline) provides objective biochemical confirmation of mast cell degranulation as the mechanism, supporting a diagnosis of anaphylaxis and triggering the appropriate allergist referral, epinephrine prescription, and allergen avoidance protocol. Negative acute tryptase does not exclude anaphylaxis — food-triggered anaphylaxis (particularly to peanuts) is characteristically associated with normal or minimally elevated tryptase despite severe clinical reactions, and the assay is more sensitive for venom and drug-triggered events. In the baseline context — collected at least 24 hours after any acute allergic event, in a clinically stable patient not experiencing an active reaction — serum tryptase reflects the constitutive alpha-tryptase released by resting mast cells in proportion to total body mast cell burden. Persistently elevated baseline tryptase is the primary biochemical screening tool for systemic mastocytosis, mast cell activation syndrome (MCAS), and the recently characterised hereditary alpha-tryptasaemia (HAT) — a common autosomal dominant condition caused by TPSAB1 gene duplication, present in approximately 4–6% of the general population, associated with elevated baseline tryptase and a clinical phenotype of heightened allergic reactivity, connective tissue features, and autonomic dysregulation. Baseline tryptase above 20 ng/mL constitutes a WHO major diagnostic criterion for systemic mastocytosis and mandates bone marrow biopsy.
What does the Serum Tryptase test measure?
Tryptase is a serine protease stored in the secretory granules of mast cells and, to a much lesser extent, basophils — making it the most mast-cell-specific protease measurable in serum. Two major forms exist with distinct release kinetics and clinical significance. Beta-tryptase (β-tryptase) is stored in mast cell granules in its mature, enzymatically active tetrameric form and is released acutely during mast cell degranulation — it is the form responsible for the transient tryptase spike following anaphylaxis, peaking 30–120 minutes after the triggering event and returning to baseline within 6–24 hours, with a serum half-life of approximately 2 hours. Alpha-tryptase (α-tryptase) is constitutively secreted as a proform (pro-alpha-tryptase) by resting mast cells in proportion to total mast cell number — its serum level reflects the steady-state mast cell burden and constitutes the dominant component of baseline (resting) tryptase measured between allergic episodes. Most clinical serum tryptase assays measure total tryptase — the combined alpha and beta fractions — rather than individual isoforms, meaning baseline total tryptase predominantly reflects alpha-tryptase (constitutive mast cell mass marker) and acute post-reaction tryptase reflects the superimposed beta-tryptase spike above the individual's baseline.
Serum tryptase serves two distinct and temporally separated clinical roles that are determined by when the specimen is collected relative to any acute mast cell activation event. Acute tryptase measurement — collected 30–120 minutes following a suspected anaphylactic or severe allergic reaction — confirms mast cell degranulation as the mechanism of the acute event, with a rise above the individual's personal baseline meeting diagnostic criteria for anaphylaxis per WAO and AAAAI guidelines. The validated formula for a diagnostically significant acute rise is: peak tryptase ≥ 1.2 × (individual baseline tryptase) + 2 ng/mL. Baseline tryptase measurement — collected at least 24 hours after any acute event in a clinically stable patient — quantifies the constitutive mast cell burden and is the primary diagnostic and monitoring marker for systemic mastocytosis, mast cell activation syndrome (MCAS), and hereditary alpha-tryptasaemia (HAT). A baseline tryptase persistently above 20 ng/mL is a WHO major diagnostic criterion for systemic mastocytosis, requiring bone marrow biopsy for confirmation. Elevated baseline tryptase in the 11.4–20 ng/mL range requires contextualisation with clinical features to distinguish early or indolent systemic mastocytosis, MCAS, hereditary alpha-tryptasaemia, chronic kidney disease, or myeloid malignancy as the underlying cause.
Why is the Serum Tryptase test ordered?
- Acute anaphylaxis confirmation — collected 30–120 minutes following a suspected anaphylactic reaction, venom sting, severe drug reaction, or unexplained cardiorespiratory collapse; a baseline specimen at least 24 hours later is mandatory for calculating the diagnostic threshold and establishing the individual's personal baseline for future reference
- Systemic mastocytosis evaluation — persistently elevated baseline tryptase (>20 ng/mL) in a patient with urticaria pigmentosa, unexplained osteoporosis, recurrent anaphylaxis, hepatosplenomegaly, or other features consistent with mast cell disease, where tryptase elevation is a WHO major diagnostic criterion triggering bone marrow biopsy referral
- Mast cell activation syndrome (MCAS) workup — recurrent multisystem episodes consistent with mast cell mediator release (flushing, urticaria, angioedema, diarrhoea, hypotension, tachycardia, neurological symptoms) where baseline tryptase and acute episode tryptase are assessed alongside 24-hour urine N-methylhistamine, prostaglandin D2 metabolites, and heparin to satisfy MCAS diagnostic criteria
- Hereditary alpha-tryptasaemia (HAT) investigation — elevated baseline tryptase (typically 8–20 ng/mL) in a patient with a family history of elevated tryptase, heightened allergic reactivity, hypermobility or connective tissue features, dysautonomia, or postural orthostatic tachycardia syndrome (POTS), where TPSAB1 gene copy number analysis (ddPCR) is the confirmatory test
- Recurrent unexplained anaphylaxis investigation — establishing a personal tryptase baseline in patients with a history of recurrent severe allergic reactions, enabling future acute episodes to be evaluated against the confirmed individual reference value rather than the population reference range
- Venom immunotherapy and allergen immunotherapy safety monitoring — baseline tryptase as a risk stratification marker before commencing venom or allergen immunotherapy, given that elevated baseline tryptase predicts higher risk of systemic reactions during desensitisation protocols
- Unexplained osteoporosis in a younger patient — elevated tryptase in the context of unexplained bone density loss in adults under 65 raises the possibility of indolent systemic mastocytosis with bone marrow infiltration as a contributing cause, particularly when vertebral fractures occur without adequate trauma
- Integrative and functional medicine practitioners evaluating mast cell activation in complex multi-system presentations — serum tryptase as the first-line objective biomarker in patients presenting with chronic multisystem allergic, gastrointestinal, neurological, and dysautonomic features consistent with MCAS, alongside N-methylhistamine, prostaglandin D2 metabolites, and clinical symptom criteria
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — however, specimen collection timing relative to any acute allergic or anaphylactic event is the critical pre-analytical variable superseding all other preparation requirements. For acute post-reaction specimens: collect between 30 and 120 minutes after event onset for peak tryptase assessment. For baseline specimens: collect at least 24 hours after any acute mast cell activation event and in the absence of current acute symptoms.
Collection method
Venipuncture at patient service centre
Turnaround
1–3 business days
Collection notes
Standard venipuncture into a serum separator tube (SST / gold top). For acute specimens, the exact time of specimen collection and the exact time of acute event onset must be recorded on the requisition form — without these timestamps, the acute tryptase result cannot be clinically interpreted. For baseline specimens, document that the patient is clinically stable and that at least 24 hours have elapsed since any acute reaction. Document on the requisition form: (1) collection time and event onset time (acute specimens); (2) whether this is a baseline or acute specimen; (3) prior tryptase baseline values if available — essential for applying the diagnostic formula; (4) known or suspected systemic mastocytosis, MCAS, or HAT diagnosis; (5) current medications — corticosteroids and antihistamines do not affect tryptase levels but are relevant for clinical context; (6) renal function status — significant CKD elevates baseline tryptase independently. # REVIEWER FLAG: Confirm Quest Diagnostics tube type, minimum serum volume, and any special handling requirements for tryptase before publication. Confirm whether Quest provides the ImmunoCAP tryptase assay (Thermo Fisher) specifically.
Specimen requirements
Minimum 0.5 mL serum. Centrifuge and separate serum within 2 hours of collection. Stable at 2–8°C for up to 7 days; stable frozen at −20°C for extended storage. For acute specimens — process and ship with clinical urgency to minimise pre-analytical delay, though tryptase is relatively stable in separated serum at refrigerator temperature. # REVIEWER FLAG: Confirm minimum volume and stability data with Quest Diagnostics assay documentation.
What can affect Serum Tryptase results?
Beta-tryptase released during acute mast cell degranulation peaks in serum at 30–120 minutes post-event and declines toward the individual's baseline within 6–24 hours, with a half-life of approximately 2 hours. Specimens collected too early (under 30 minutes) may miss the peak; specimens collected too late (beyond 4–6 hours post-event) may show only partial elevation above baseline; and specimens collected more than 24 hours post-event reflect the baseline tryptase level rather than the acute degranulation response. Precise collection timing documentation is the single most critical pre-analytical variable for acute tryptase interpretation — the timestamp of specimen collection relative to the onset of the acute event must be recorded on the requisition form.
The validated diagnostic threshold for anaphylaxis-related acute tryptase rise — peak ≥ 1.2 × (individual baseline) + 2 ng/mL — requires knowledge of the patient's personal resting baseline tryptase. Without a baseline, a post-reaction tryptase within the population reference range (<11.4 ng/mL) cannot be excluded as a significant rise in a patient with a very low personal baseline (e.g., a baseline of 2 ng/mL and a peak of 8 ng/mL represents a significant proportional rise that satisfies the formula). Establishing a personal baseline tryptase — at least 24 hours after any acute event — is best practice for all patients with a history of anaphylaxis or severe allergic disease.
Tryptase is cleared partially by renal filtration. Chronic kidney disease — particularly eGFR below 30 mL/min/1.73m² — reduces tryptase clearance, producing elevated baseline serum tryptase independent of mast cell mass or activation. Serum creatinine and eGFR must always be assessed alongside tryptase interpretation; elevated tryptase in a patient with significant renal impairment requires clinical contextualisation against the degree of renal function loss before mast cell disease is investigated.
Mast cells share a common precursor with basophils and myeloid lineages; myeloproliferative neoplasms and myelodysplastic syndrome can drive clonal mast cell expansion and elevated tryptase production independent of systemic mastocytosis. Elevated baseline tryptase in the context of cytopenias, macrocytosis, or other haematological abnormalities should prompt haematological review and consideration of bone marrow biopsy beyond the standard mastocytosis pathway.
HAT is an autosomal dominant condition caused by duplication of the TPSAB1 gene encoding alpha-tryptase, present in approximately 4–6% of the general population. Additional TPSAB1 gene copies produce constitutively elevated baseline alpha-tryptase — typically 8–20 ng/mL — independent of mast cell disease. HAT is the most common identifiable cause of mildly to moderately elevated baseline tryptase in clinical practice and is confirmed by TPSAB1 copy number analysis (droplet digital PCR — ddPCR). Distinguishing HAT from early indolent systemic mastocytosis requires this genetic testing, as both conditions produce elevated baseline tryptase in the same range.
Significant in vitro haemolysis releases cellular contents into serum, which can interfere with immunoassay optical measurements and potentially produce artefactually elevated tryptase readings. Haemolysed specimens should be rejected and recollected. # REVIEWER FLAG: Confirm Quest Diagnostics specimen rejection criteria for haemolysis for the tryptase assay.
What do Serum Tryptase results mean?
Elevated
Elevated tryptase requires interpretation in the context of collection timing, clinical presentation, and the patient's established personal baseline. In the acute context — collected 30–120 minutes post-reaction — a peak tryptase meeting the formula threshold (≥ 1.2 × baseline + 2 ng/mL, or peak >11.4 ng/mL without a known baseline) confirms mast cell degranulation consistent with anaphylaxis and warrants allergist referral, epinephrine auto-injector prescription, and allergen investigation. In the baseline context — collected at least 24 hours post-event in a stable patient — a tryptase persistently above 20 ng/mL is a WHO major criterion for systemic mastocytosis requiring haematology referral and bone marrow biopsy. A baseline tryptase between 11.4–20 ng/mL warrants investigation for indolent systemic mastocytosis, hereditary alpha-tryptasaemia (TPSAB1 ddPCR), chronic kidney disease (eGFR), and myeloid malignancy. Even a baseline tryptase above 8 ng/mL should prompt consideration of HAT in a patient with a compatible clinical phenotype (heightened allergy, connective tissue features, dysautonomia) — HAT is markedly underdiagnosed and the 11.4 ng/mL population reference range does not capture all clinically significant HAT cases.
Normal
A baseline tryptase below 11.4 ng/mL in a clinically stable patient substantially reduces the probability of systemic mastocytosis and HAT as causes of elevated mast cell burden, though it does not exclude episodic MCAS, food-triggered anaphylaxis (which characteristically produces minimal tryptase elevation), or early indolent mast cell disease with a modest baseline. A normal acute tryptase collected within the appropriate time window following a suspected anaphylactic reaction does not exclude anaphylaxis — particularly for food-triggered reactions — and clinical diagnosis of anaphylaxis should not be dismissed solely on the basis of a normal tryptase result.
Reduced
Baseline tryptase below 5 ng/mL in a symptomatic patient with a clinical presentation consistent with MCAS does not exclude mast cell activation. MCAS can occur with a normal or low-normal baseline tryptase, particularly when mast cell activation is episodic rather than continuous — in this context, tryptase collected within 30–120 minutes of a symptomatic episode may show a diagnostic rise above baseline even if the resting baseline is within the reference range. Complementary mast cell mediator tests — 24-hour urine N-methylhistamine, prostaglandin D2 metabolites, and heparin — should be assessed when MCAS is clinically suspected despite a normal baseline tryptase.
Note: The most critical interpretive caveat is the absolute necessity of specimen collection timing documentation for acute tryptase — a result without a timestamped collection time relative to the acute event cannot be meaningfully interpreted. The second critical caveat is the requirement for a personal baseline tryptase for applying the diagnostic threshold formula — population reference ranges are insufficient substitutes for the individual's own resting value. Practitioners should also note that food-triggered anaphylaxis — the most common trigger in paediatric and community anaphylaxis — characteristically produces attenuated or normal acute tryptase responses compared to venom and drug-triggered events, likely due to preferential mucosal mast cell activation with limited systemic tryptase spillover; a normal tryptase should not be used to dismiss a clinical diagnosis of food anaphylaxis. Finally, the ImmunoCAP tryptase assay (Thermo Fisher) is the dominant clinical platform but is not the only assay in use — results from different platforms are not directly cross-comparable, and practitioners should confirm Quest Diagnostics' specific assay before comparing values across laboratories or over time if the testing laboratory changes.
Frequently asked questions
Serum tryptase measures total tryptase — the alpha and beta fractions of this mast-cell-specific protease. It has two distinct clinical applications determined by collection timing. Acute tryptase — collected 30–120 minutes after a suspected anaphylactic reaction — confirms mast cell degranulation and biochemical anaphylaxis. Baseline tryptase — collected at least 24 hours post-event in a stable patient — reflects constitutive mast cell burden and is the primary screening and monitoring marker for systemic mastocytosis, mast cell activation syndrome, and hereditary alpha-tryptasaemia.
How to access the Serum Tryptase test
The Serum Tryptase reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: May 23, 2026
Last reviewed: May 23, 2026
- Valent P, et al. Mast cell activation syndrome: Importance of consensus criteria and call for research. J Allergy Clin Immunol. (2021)
- Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. (2006)
- Lyons JJ, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. (2016)
- Sampson HA, et al. Second symposium on the definition and management of anaphylaxis: summary report — Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. (2006)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.